Evidence Updates
What changed, and why.
A grade that never moves isn't rigorous — it's just old. This is the dated, public record of every change we've made to an ingredient's evidence status, with the reasoning attached. Downgrades included; especially downgrades.
July 12, 2026
10 changesNew profile at Grade C, with explicit serotonergic-interaction cautions.
Prompted by: Sleep & recovery cluster expansion.
New profile at Grade C for sleep/relaxation, on limited human data.
Prompted by: Sleep & recovery cluster expansion.
New profile at Grade C for sleep/mood-adjacent roles, with conservative interaction cautions.
Prompted by: Sleep & recovery cluster expansion.
New profile at Grade C — a well-tolerated, well-absorbed magnesium form with limited direct human cognition/sleep trials at this specific form.
Prompted by: Sleep & recovery / micronutrient batch.
New profile, published at Grade B on independent (non-sponsor) evidence: a meta-analysis of 19 randomized trials found melatonin reduced sleep-onset latency and modestly increased total sleep time. Graded for sleep onset specifically — not as a daytime nootropic.
Prompted by: Sleep & recovery cluster expansion; new Hormone category.
New profile at Grade C for sleep/relaxation, on limited human data.
Prompted by: Sleep & recovery cluster expansion.
Published straight into Graded Out on a safety-and-null-evidence basis. Randomized trials in replete older adults show no cognitive or dementia-prevention benefit (SELECT, PREADViSE), and the window between adequate and excessive intake is narrow.
Prompted by: Micronutrient batch review.
New profile at Grade C for sleep; trials are mixed and heterogeneous in preparation.
Prompted by: Sleep & recovery cluster expansion.
Published straight into Graded Out on a safety veto. In replete adults the cognitive-prevention evidence is null (PREADViSE), and high-dose supplementation carries a documented safety signal — repletion of a true deficiency is not a nootropic effect.
Prompted by: Micronutrient batch review.
New profile at Grade C — essential for cognition when deficient, but supplementation in replete adults is a repletion story, not a nootropic one.
Prompted by: Micronutrient batch review.
July 11, 2026
6 changesDowngraded from B to C. Acute cognitive effects appear in small trials but do not replicate consistently enough across doses and populations to hold a B.
Prompted by: Full-library evidence & data refresh.
Downgraded from B to C. The cognition signal comes from a small number of trials with a specific bioavailable form; the broader, independent replication needed for a B is not there yet.
Prompted by: Full-library evidence & data refresh.
Downgraded from B to C. Cognitive-benefit trials are promising but limited in number and largely in specific populations, short of the consistent replication a B requires.
Prompted by: Full-library evidence & data refresh.
Downgraded from B to C. Acute dosing raises cerebral blood flow but did not improve cognition in healthy adults; the only positive cognition data come from a narrower postmenopausal-women population.
Prompted by: Full-library evidence & data refresh.
Downgraded from B to C. The working-memory effect is real in the trials that exist but rests on a single branded extract with limited independent replication.
Prompted by: Full-library evidence & data refresh.
Downgraded from B to C. The attention/memory result rests on a single acute-dose trial in healthy adults; a B needs independent replication that does not yet exist.
Prompted by: Full-library evidence & data refresh.
July 7, 2026
4 changesGraded out, not merely low-graded. The strongest human data are 1960s–70s pediatric trials since abandoned; there are essentially no adequate positive RCTs for memory or focus in healthy adults, and the acetylcholine mechanism is not well substantiated.
Prompted by: Full-library evidence audit.
Downgraded from B to C. Acute cognitive effects appear in some trials but replicate inconsistently across doses and extracts, so the evidence is limited rather than moderate.
Prompted by: Full-library evidence audit.
Downgraded from B to C. The stronger data sit in age-related decline and soy-derived PS trials; the healthy-adult, focus-specific evidence at label-realistic doses is thinner than a B implies.
Prompted by: Full-library evidence audit.
Downgraded from B to C. The human trials are mostly small, short, and heterogeneous in outcome measure, and several are sponsor-linked — not enough consistent, independent replication to hold a B.
Prompted by: Full-library evidence audit; introduction of the Graded Out status.
Get the changes as they ship
We publish an update whenever a grade moves, an ingredient is graded out, or a new profile lands. Follow the RSS feed, or join the waitlist below — evidence-update notes go out to the list, never spam.
Less noise. More signal.
Get the Clean Focus Stack Guide
Join the waitlist for early access to Signal State Core and we'll send the guide — plus the ingredient research behind it. No spam, just signal.